Program Announcement for the Defense Health Agency

Parkinson's Research Program
Early Investigator Research Award

Funding Opportunity Number: HT942526PRPEIRA

Pre-Application Due: October 23, 2026

Application Due: November 6, 2026

This program announcement must be read in conjunction with the General Application Instructions, version CD26_01.

Content

Before You Begin

- **Active SAM.gov, eBRAP.org and Grants.gov registrations are required for application submission.** User registration for each of these websites can take several weeks or longer. Each applicant must ensure their registrations are active and up to date prior to application preparation.
- **Read this funding opportunity announcement in the order it is written before beginning to prepare application materials.** It is the responsibility of the applicant to determine whether the proposed research meets the intent of this funding opportunity and that all parties meet eligibility requirements.
- **To support application preparation, additional resources are available** including an application process FAQ, a Guide for Intragovernmental & Intramural Applicants and a CDMRP Video Series detailing the application process.

Who to Contact for Support

eBRAP Help Desk

301-682-5507
help@eBRAP.org

Questions regarding funding opportunity submission requirements, as well as technical assistance related to pre-application or intramural application submission.

Grants.gov Support Center

800-518-4726
International: 1-606-545-5035
support@grants.gov

Questions regarding Grants.gov registration and Workspace.

This document uses internal links; you can go back to where you were by pressing the Alt + left arrow keys (Windows) or command + left arrow keys (Macintosh) on your keyboard.

Click to be taken to additional guidance and instructions within the General Application Instructions (GAI).

1. Basic Information About the Funding Opportunity

Summary: The fiscal year 2026 (FY26) Parkinson's Research Program (PRP) Early Investigator Research Award (EIRA) supports Parkinson's disease (PD) research for investigators in the early stages of their careers. The FY26 EIRA offers two funding levels, which align to the research career stage of the Principal Investigator (PI). Funding Level 1 (for fellows) requires the investigator to receive guidance from a designated Mentor, whereas Funding Level 2 (for early-career independent investigators) does not. Proposed research must address at least one of the four FY26 PRP Focus Areas.

Distinctive Features:

- The Early Investigator is considered the PI of the application and must exhibit strong potential for and commitment to pursuing a career as an investigator at the forefront of PD research; however, the PI is not required to have previous PD research experience.
- **Funding Level 1:** Applications must include at least one Mentor appropriate to the proposed research project who has experience in PD research and mentoring, as demonstrated by a record of active funding, recent publications, and successful mentorship. The selected Mentor(s) should also demonstrate a clear commitment to the development of the PI toward independence as a PD researcher. ***Preliminary data are encouraged but not required*.**
- **Funding Level 2:** Mentor not required. ***Preliminary data are required***.
- Clinical trials are ***not*** allowed.

Funding Details: The Congressionally Directed Medical Research Programs (CDMRP) expects to allot roughly $4.2M to fund approximately seven Early Investigator Research Award applications with total cost caps of $0.3M for Funding Level 1 awards and $1.0M for Funding Level 2 awards. The maximum period of performance is 2 years. It is anticipated that awards made from this FY26 funding opportunity will be funded with FY26 funds, which will expire for use on September 30, 2032. Awards supported with FY26 funds will be made no later than September 30, 2027.

Submission and Review Dates and Times

- **Pre-Application (Letter of Intent) Submission Deadline:** 5:00 p.m. Eastern Time (ET), October 23, 2026
- **Application Submission Deadline:** 11:59 p.m. ET, November 6, 2026
- **End of Application Verification Period:** 5:00 p.m. ET, November 13, 2026
- **Confidential Letters of Recommendation Submission Deadline:** 5:00 p.m. ET, November 13, 2026
- **Peer Review:** January 2027
- **Programmatic Review:** March 2027

Announcement Type: Initial

Funding Opportunity Number: HT942526PRPEIRA

Assistance Listing Number: 12.420

2. Eligibility Information

2.1. Eligible Applicants

2.1.1. Organization

Extramural and intramural U.S. Department of War (DOW) organizations are eligible to apply, ***including foreign and domestic organizations, for-profit and nonprofit organizations, and public or private entities***.

2.1.2. Principal Investigator

Postdoctoral fellows, clinical fellows, or independent investigators within 10 years of advanced degree or residency training completion, or equivalent, who are affiliated with an eligible organization are eligible to be named PI on the application, regardless of ethnicity, nationality or citizenship status.

- **Funding Level 1** applications are intended to support postdoctoral fellows, clinical fellows, or equivalent. Applications ***must*** include at least one mentor who has experience in PD research and mentoring as demonstrated by a record of active funding, recent publications, and successful mentorship.
- **Funding Level 2** applications are intended to support early-career, independent investigators within 10 years of advanced degree or residency training completion, or equivalent. Applications do not require a mentor.

An investigator may be named on only one FY26 PRP EIRA application as the PI.

2.2. Cost Sharing

Cost sharing is not an eligibility requirement.

2.3. Other

Awards are made to eligible ***organizations***, not to individuals. Refer to the GAI for additional recipient qualification requirements.

3. Program Description

The Defense Health Agency Contracting Activity (DHACA) is soliciting applications to this funding opportunity using delegated authority provided by United States Code, Title 10, Section 4001 (10 USC 4001). The CDMRP is the program office managing this FY26 funding opportunity as part of the Parkinson's Research Program (PRP). The CDMRP is located within the Defense Health Agency Research and Development (DHA R&D), which is a part of the Department of Defense, DOD, herein referred to using the secondary title Department of War, DOW. In FY22, Congress transitioned the Neurotoxin Exposure Treatment Parkinson's Program to PRP and broadened the research from neurotoxin exposure treatment Parkinson's disease (PD) research to all types of PD research. Appropriations for the PRP from FY22 through FY24 totaled $48 million (M). The FY26 appropriation is $16M.

The vision of the PRP is to improve the health and lives of people with, or at risk for, Parkinson's disease through innovative research that translates to clinically meaningful treatments.

The mission of the PRP is to support high impact research that intends to decrease risk, slow progression, or ease symptoms of Parkinson's disease to benefit Service Members and their Families, Veterans and the general public.

The PRP seeks to support research that is relevant to the health care needs of Service Members, Veterans, and their Families, and/or Family readiness of Service Members. As such, applications must demonstrate how the proposed research will decrease the burden of Parkinson's disease on Service Members, their dependents, Veterans and other military beneficiaries (i.e., Family members of retirees). Inclusion of Service Members, Veterans, or other military beneficiary populations is not required, but the proposed research should be applicable towards and benefit those groups.

3.1. PRP Focus Areas

All applications ***must*** address at least one of the following FY26 PRP Focus Areas:

- Understanding how Parkinson's disease biological and clinical heterogeneity impacts disease presentation, clinical course and therapeutic outcomes, from prodromal to late-stage Parkinson's disease
- Development and characterization of in vitro model systems that approximate in vivo cellular and system complexity
- Biological mechanisms or biomarkers, such as clinical, fluid, imaging, tissue, and devices, of unmet medical needs that could lead to the development of treatments for PD. Applications can utilize laboratory models through to human participants. Examples of unmet medical needs of interest include, but are not limited to:
    - Non-motor symptoms:
        - Autonomic
        - Cognitive
        - Fatigue
        - Olfaction
        - Pain

    - Psychiatric
    - Sensory
    - Sleep and circadian rhythm disruptions
  - Motor symptoms
    - Dyskinesia
    - Dystonia
    - Gait and balance
    - Tremor
- Interventions that address unmet medical needs of PD that include both clinical and preclinical models. Examples of interventions of interest include, but are not limited to:
  - Biological
  - Pharmacological
  - Non-pharmacological
  - Surgical
  - Non-surgical devices
  - Non-invasive central nervous system stimulation

3.2. Intent of the Early Investigator Research Award

To expand PD research capacity and address understudied PD research areas, the PRP Early Investigator Research Award (EIRA) supports PD research conducted by investigators in the early stages of their careers. The Early Investigator is considered the Principal Investigator (PI) of the application and must exhibit strong potential for, and commitment to, pursuing a career as an investigator at the forefront of PD research; however, the PI is not required to have previous PD research experience. ***The FY26 PRP EIRA offers two levels of funding, which align to the PI's research career stage:***

- **Funding Level 1** applications are intended to support postdoctoral fellows, clinical fellows, or equivalent. Applications ***must*** include at least one mentor.
- **Funding Level 2** applications are intended to support early-career, independent investigators within 10 years of advanced degree or residency training completion, or equivalent. Applications do not require a mentor.

3.2.1. Key Elements for the EIRA

All applications for the EIRA are to be written by the PI, with appropriate direction from the Mentor(s).

- **Principal Investigator:** The EIRA supports early-career investigators exploring innovative, high-impact ideas or new technologies applicable to PD research. The application should demonstrate the PI's potential for, and commitment to, pursuing a career in treatment-related PD and/or patient care research. Funding Level 1 applications ***must*** include at least one Mentor, appropriate to the proposed research project, who has experience in PD research and mentoring as demonstrated by a record of active funding, recent publications,

and successful mentorship. Funding Level 2 applications are not required to include a Mentor.

- **Research Strategy and Feasibility:** The scientific rationale and experimental methodology should demonstrate critical understanding and in-depth analysis of the neurodegenerative effects of PD. Experimental strategies may be novel or may be based on strong rationale derived from previously published data, presented preliminary data, or literature review. The feasibility of the research design and methods should be well-defined, and a clear plan should be articulated as to how the proposed goals of the project can be achieved.
    - ***Preliminary data are encouraged for Funding Level 1 applications.***
    - ***Preliminary data are required for Funding Level 2 applications.***

  Any unpublished preliminary data provided should originate from the PI, Mentor(s), or member(s) of the collaborating team. The preliminary data must support the feasibility of the study.
- **Impact:** The proposed research, if successful, should have an impact on an area of paramount importance to PD. The application must clearly and explicitly describe the potential short-term and long-term impacts of the proposed study and convey its level of significance. The research should benefit individuals with PD.
- **Researcher Development Plan *(Funding Level 1 Applications only)*:** The application must outline an individualized Researcher Development Plan. The Researcher Development Plan should include a clearly articulated strategy for acquiring the necessary skills, competence, and expertise that will enable the PI to successfully complete the proposed research project and foster the PI's development as an independent PD researcher. An environment appropriate to the proposed mentoring and research at the PI's institution must be clearly described. Additional necessary resources and/or mentorship may be provided through collaboration(s) with other institutions. If the PI will be utilizing resources at another institution to successfully complete the proposed project, then the PI is strongly encouraged to designate a co-Mentor at the collaborating institution.

3.2.2. Other Important Considerations for the EIRA

In accordance with the National Defense Authorization Act for Fiscal Year 2026, Section 732, the CDMRP does ***not*** support the conduct of painful research (U.S. Department of Agriculture pain category D or E) involving domestic cats or dogs, except for studies relating to military or service animals.

Clinical trials are not allowed within this funding opportunity; however, clinical research involving human subjects, secondary use of human data, and/or use of human anatomical substances is permitted.

All projects should adhere to a core set of standards for rigorous study design and reporting to maximize the reproducibility and translational potential of clinical and preclinical research, such as those described in the STROBE, CONSORT, SPIRIT and ARRIVE 2.0 guidelines.

Applications from investigators within the DOW and applications involving multidisciplinary collaborations among academia, industry, the DOW, the U.S. Department of Veterans Affairs (VA) and other federal government agencies are highly encouraged. These relationships can leverage knowledge, infrastructure and access to unique clinical populations that the collaborators bring to the research effort, ultimately advancing research that is of significance to Service Members, Veterans, their Families and the American Public. If the proposed research

relies on access to unique resources or databases, the application must describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research.

3.3. Funding Instrument

The funding instrument for awards made under the program announcement will be grants (31 USC 6304).

3.4. Funding Details

Period of Performance: The maximum period of performance is **2** years.

Cost Cap: The application's total costs budgeted for the entire period of performance should not exceed **$0.3M** for Funding Level 1 awards and **$1.0M** for Funding Level 2 awards. If indirect cost rates have been negotiated, indirect costs are to be budgeted in accordance with the organization's negotiated rate. Collaborating organizations should budget associated indirect costs in accordance with each organization's negotiated rate.

All direct and indirect costs of any subaward or contract must be included in the direct costs of the primary award.

The applicant may request the entire maximum funding amount for a project that may have a period of performance less than the maximum **2** years.

The appropriateness of the budget for the proposed research will be assessed during peer review.

Direct Cost Restrictions: For this award mechanism, direct costs:

May be requested for (not all-inclusive):

- Travel in support of multi-institutional collaborations.
- Costs for ***one*** investigator to travel to ***one*** scientific/technical meeting per year. The intent of travel to scientific/technical meetings should be to present project information or disseminate project results from the PRP EIRA.

Must not be requested for:

- Costs for travel to scientific/technical meeting(s) beyond the limits stated above.
- Clinical trial costs.

4. Application Contents and Format

4.1. Application Overview

Application submission is a two-step process requiring both a ***pre-application*** submitted via the Electronic Biomedical Research Application Portal (eBRAP) and a ***full application*** submitted through eBRAP or Grants.gov. Depending on the submission portal, certain aspects of the application will differ.

Intramural DOW organizations submitting a full application should follow instructions for submission through eBRAP.

Extramural organizations submitting a full application must follow instructions for submission through Grants.gov.

4.2. Pre-Application Components

Pre-application submissions must include the following components.

Letter of Intent (LOI) (one-page limit): Provide a brief description of the research to be conducted. Include the FY26 PRP Focus Area(s) under which the application will be submitted.

List of Individuals Providing Confidential Letters of Recommendation: Enter contact information for a minimum of two and maximum of three individuals (including the Mentor, if applicable) who will provide letters of recommendation. Each individual will receive an email generated from eBRAP containing specific instructions on how to upload their letter.

4.3. Full Application Components

Each application submission must include the completed full application package for this program announcement. See Appendix 1 for a checklist of the full application components.

(a) SF424 Research & Related Application for Federal Assistance Form *(Grants.gov submissions only)*:

IMPORTANT: *When completing the SF424 R&R, enter the* ***eBRAP log number*** *assigned during pre-application submission into* ***Block 4a – Federal Identifier****.*

(b) Attachments:

Each attachment of the full application components must be uploaded as an individual file in the format specified and in accordance with the formatting guidelines in the GAI.

- **Attachment 1: Project Narrative (Eight-page limit): Upload as "ProjectNarrative.pdf".**

  Describe the proposed project in detail using the outline below. The Project Narrative must be written by the PI. The Funding Level 1 Project Narrative should show evidence of appropriate direction from the Mentor(s).

  - **Principal Investigator:** The PI should describe how their achievements (as reflected by academic performance, awards, honors, and/or previous publications and funding) indicate the potential for a successful career as a PD researcher. The PI should describe how their stated career goals demonstrate a strong personal commitment to pursuing an independent career as a leader in PD research. The PI

should describe how their proposed level of effort, if not 100%, is appropriate for successful completion of the proposed work.

- **Background:** Present the ideas and reasoning behind the proposed research. The application must provide a sound scientific rationale to support the proposed project and its feasibility as established through the demonstration of logical reasoning and critical review and analysis of published literature; include relevant literature citations. ***The presentation of preliminary and/or published data to support the proposed research project is required for Funding Level 2 applications. Any unpublished preliminary data provided should originate from the laboratory of the PI(s) or member(s) of the research team.***
- **Hypothesis or Objective:** State the hypothesis to be tested or the objective to be reached. State concisely the new concept, theory, paradigm, and/or method that addresses an important problem in PD research and/or patient care.
- **Specific Aims:** Concisely explain the proposed research project's specific aims to be funded by this application. If the proposed research project is part of a larger study, ***present only tasks that this award would fund.***
- **Research Strategy and Feasibility:** Describe the experimental design, methods, and analyses, including appropriate controls, in sufficient detail for evaluation. Clearly describe how data will be collected and analyzed in a manner that is consistent with the study objectives. Consult appropriate guidelines to ensure relevant aspects of rigorous and reproducible research are adequately planned for and, ultimately, reported. Describe availability of, access to, and quality control for all data and/or critical reagents, and/or cohorts, where relevant.
- If animal studies are proposed, describe how they will be conducted in accordance with the ARRIVE guidelines 2.0 to achieve reproducible and rigorous results, including the choice of model and the endpoint/outcomes to be measured.
- If proposing clinical research:
  - Describe the study population. Describe the rationale for the selection of subjects/samples/data. Explain how the selection is appropriate for addressing the study aims. Further details of research involving human subjects or human biological substances will be required in **Attachment 11: Human Subjects/Samples Acquisition and Safety Procedures**, as applicable. ***Clinical trials are not allowed.***
  - Describe the strategy for the inclusion of women and minorities appropriate to the objectives of the study, including a description of the composition of the proposed study population in terms of sex, race and ethnic group. If limiting inclusion of any group by sex, race or ethnicity, provide justification related to the scientific goals. Studies utilizing human biospecimens or datasets that cannot be linked to a specific individual, ethnicity or race (typically classified as exempt from Institutional Review Board [IRB] review) are exempt from this requirement. Anticipated enrollment table(s) with the proposed enrollment distributed on the basis of sex, race and ethnicity should be provided as part of **Attachment 11: Human Subjects/Samples Acquisition and Safety Procedures**.
  - If the proposed research involves access to military and/or VA patient populations and/or DOW or VA resources or databases, describe the access at the time of submission and include a plan for maintaining access as needed

throughout the proposed research. Also include a plan for obtaining any required data sharing, memorandum of understanding or other agreements required to access and publish data. Refer to the General Application Instructions, Appendix 4, for additional considerations.

- **Statistical Analysis Plan:** Describe the statistical model and data analysis plan with respect to the study objectives. Include a power analysis to demonstrate that the sample size is appropriate to meet the objectives of the study. Describe how data will be reported and how it will be assured that the documentation will support a regulatory filing with the U.S. Food and Drug Administration (FDA), if applicable.
- Address potential limitations and present alternative methods and approaches.
- Explain how the research can be completed within the proposed period of performance.

- **Attachment 2: Supporting Documentation: Combine and upload as a single file named "Support.pdf".**

  There are no page limits for these components unless otherwise noted. Include only components described below; inclusion of items not requested or viewed as an extension of the Project Narrative will result in the removal of those items or may result in administrative withdrawal of the application.

  - **References Cited:** List the references cited in the Project Narrative using a standard reference format (include URLs, if available).
  - **List of Abbreviations, Acronyms and Symbols:** Provide a list of abbreviations, acronyms and symbols.
  - **Facilities, Existing Equipment and Other Resources:** Describe the facilities and equipment available for performance of the proposed project; include any additional facilities or equipment proposed for acquisition at no cost to the award. Indicate whether government-furnished facilities or equipment are proposed for use. If so, reference the original or present government award under which the facilities or equipment items are now accountable. There is not a standardized form for this information.
  - **Publications and/or Patents:** Include a list of relevant publication URLs and/or patent abstracts. If articles are not publicly available, then copies of up to five published manuscripts may be included in Attachment 2. Extra items will not be reviewed.
  - **Letters of Support (two-page limit per letter is recommended):** Provide individual letters signed by collaborating individuals and/or organizational officials demonstrating that the PI has the support and resources necessary for the proposed work. If applicable, provide a letter of support, signed by the lowest-ranking person with approval authority, confirming participation of intramural DOW collaborator(s) and/or access to military populations, databases or DOW resources. If applicable, provide a letter of support signed by the VA Facility Director(s), or an individual designated by the VA Facility Director(s), confirming access to VA patients, resources and/or VA research space.
  - **Sex as a Biological Variable Strategy (two-page limit is recommended):** Describe the strategy for how sex will be considered as a biological variable. This strategy should include a brief discussion of what is currently known regarding sex differences in the applicable research area. Clearly articulate how sex as a biological

variable will be factored into the data analysis plan and how data will be collected and disaggregated by sex. If needed, provide a strong rationale for proposing a single-sex study, based on justification from scientific literature, preliminary data or other relevant considerations. Refer to the CDMRP Directive on Sex as a Biological Variable in Research for additional information.

- **Data and/or Research Sharing Plan:** Describe the type of data or research resources (e.g., bio-specimen, analysis tool/software, training material) to be made publicly available as a result of the proposed work. Describe the mechanism (e.g., direct sharing, repository, mixed mode) by which data and resources generated during the period of performance will be shared with the research community and other affected communities, including clinical research participants. Include the name of the repository(ies) where scientific data and resources arising from the proposed study will be archived, if applicable. Identify and provide the rationale for any data or resources that will not be shared (e.g., for intellectual property, feasibility, cost, or other considerations). The plan should also protect participant privacy, confidential and proprietary data, and performer/third-party intellectual property. Provide a milestone plan for disseminating data/results, including when data and resources will be made available to other users. In cases where the study participant could potentially derive medical or other benefit from the information, explain whether the results of screening and/or study participation will be shared with the participant or their primary care provider, including results from any screening or diagnostic tests performed as part of the study.

  Do not submit a copy of the National Institutes of Health (NIH) Data Management and Sharing Plan or duplicate the Data Management Plan, which will be requested only after a recommendation for funding is made.

  Refer to the CDMRP Directive on Sharing Data and Research Resources for more information about the CDMRP's expectations for making data and research resources publicly available.

- **Intellectual and Material Property Plan *(if applicable)*:** Provide a plan for resolving intellectual and material property issues among participating organizations.

- **Attachment 3: Technical Abstract (one-page limit): Upload as "TechAbs.pdf".**

  Write the technical abstract using the outline below. Clarity and completeness within the space limits are highly important.

  - **Background:** Present the scientific rationale behind the proposed research project.
  - **Hypothesis/Objective(s):** State the hypothesis to be tested and/or objective(s) to be reached.
  - **Specific Aims:** State the specific aims of the study.
  - **Study Design:** Describe the study design, including appropriate controls.
  - **Impact:** Briefly describe how the proposed research project will have short-term and/or long-term impact on PD research and/or patient care.
  - **Military Relevance:** Describe how the study is relevant to military health.

- **Attachment 4: Lay Abstract (one-page limit): Upload as "LayAbs.pdf".**

  The lay abstract should address the points outlined below ***in a manner that is readily understood by readers without a background in science or medicine.*** Avoid overuse of scientific jargon, acronyms and abbreviations. ***Do not duplicate the technical abstract.***

  - Summarize the objectives and rationale for the proposed research.
  - What population will the research help, and how will it help them?
  - What are the potential applications, benefits and risks of the anticipated outcomes?
  - What are the likely contributions of the proposed research project to advancing research, patient care and/or quality of life?
  - What is the potential benefit of the proposed study and the anticipated outcomes to Service Members, Veterans and/or their Families?

- **Attachment 5: Statement of Work (three-page limit): Upload as "SOW.pdf".** Refer to eBRAP for the Suggested SOW Format.

  For guidance on preparing the SOW, refer to the Example: Assembling a Generic Statement of Work. Include milestones for data or research resource(s) sharing.

- **Attachment 6: Impact Statement (one-page limit): Upload as "Impact.pdf".** Articulate the pathway to making a clinical impact for individuals with, or at risk for, PD. The impact statement should address the points outlined below ***in a manner that is readily understood by readers without a background in science or medicine.*** Avoid overuse of scientific jargon, acronyms and abbreviations.

  - Describe a practical vision for how the short- and long-term outcomes of the proposed research will support the PRP's mission of supporting high impact research that intends to decrease risk, slow progression or ease symptoms of Parkinson's disease.
    - The short-term impact will be the anticipated outcome(s)/product(s) from the proposed research.
    - The long-term impact may be beyond the scope of the proposed research.
  - Describe how the proposed research addresses at least one of the FY26 PRP Focus Areas.
  - Explain briefly how the proposed research is relevant to the health care needs of Service Members, Veterans, their Families, and/or Family readiness of Service Members.

- **Attachment 7: Letter of Eligibility (one-page limit): Upload as "Eligibility.pdf".** Provide a letter signed by the PI and the Department Chair, Dean, or equivalent official to verify that the eligibility requirements have been met. The letter should verify that the PI is currently a postdoctoral fellow, clinical fellow, and/or no more than 10 years from their advanced degree training or residency training completion, or equivalent, as of the application deadline (Refer to eligibility criteria).

- **Attachment 8: Research Outcomes Plan (one-page limit): Upload as "Outcomes.pdf".**

  - Describe the anticipated research outcomes, including knowledge products, clinical products for development, etc.

- Describe the methods and strategies proposed to move the anticipated research outcomes to the next phase of development or clinical application after successful completion of the project.
- Detail the funding strategy to transition to the next level of investigation, development, and/or commercialization (e.g., partners, internal/external funding opportunities to be applied for).
- Demonstrate that a plan for management of intellectual property is in place.

- **Attachment 9: Researcher Development Plan (*only required for Funding Level 1 applications,* two-page limit): Upload as "ResearcherDev.pdf".**
  - Describe the plan to enable the PI to investigate a problem or question in PD research and acquire the necessary skills, competence, and expertise to successfully complete the proposed research project, and to effectively prepare him/her for a successful career as an independent PD researcher.
  - Describe the background, funding, publications, and experience of the Mentor(s) in PD research. Explain how they will guide the PI throughout the period of performance in developing toward independence in PD research. Describe their track record in mentoring early-career investigators in PD research.
  - Describe how the scientific environment at the primary institution and collaborating institution(s) are appropriate for the proposed research and career development activities, including professional interaction with established PD researchers.
  - *Do not reference or include members of the FY26 PRP Programmatic Panel.*
- **Attachment 10: Animal Research Plan (*only required for applications proposing animal studies*, five-page limit): Upload as "AnimalResPlan.pdf".**

  If the proposed study involves animals, a summary describing the animal research that will be conducted must be included in the application. Consult the ARRIVE guidelines 2.0 (Animal Research: Reporting *In Vivo* Experiments) to ensure relevant aspects of rigorous animal research are adequately planned for and, ultimately, reported. The Animal Research Plan may not be an exact replica of the protocol(s) submitted to the Institutional Animal Care and Use Committee (IACUC). The Animal Research Plan should address the following points to achieve reproducible and rigorous results for each proposed animal study:
  - Briefly describe the research objective(s) of the animal study. Explain how and why the animal species, strain, and model(s) being used can address the scientific objectives and, where appropriate, the study's relevance to human biology.
  - Summarize the procedures to be conducted. Describe how the study will be controlled.
  - Describe the randomization and blinding procedures for the study, and any other measures to be taken to minimize the effects of subjective bias during animal treatment and assessment of results. If randomization and/or blinding will not be utilized, provide justification.
  - Provide a sample size estimate for each study arm and the method by which it was derived, including power analysis calculations.

- Describe how data will be handled, including rules for stopping data collection, criteria for inclusion and exclusion of data, how outliers will be defined and handled, statistical methods for data analysis, and identification of the primary endpoint(s).

- **Attachment 11: Human Subjects/Samples Acquisition and Safety Procedures (*only required if clinical research is proposed*, no page limit): Upload as "HumProc.pdf".**

  Include the components listed below as applicable. Do not duplicate information from the Project Narrative.

  - Describe the rationale for the proposed clinical research. Describe the endpoints to be measured and outline the proposed methodology in sufficient detail to show a clear course of action and justification. Outline what measures will be used to minimize bias, including blinding and randomization procedures. Describe any other measures taken to reduce bias. Include a description of controls, as appropriate. Outline the timing and procedures planned during the follow-up period, as appropriate.
  - If the proposed clinical research was initiated using other funding prior to this application, explain the history and background of the clinical trial and declare the source of prior funding. Specifically, ***clearly articulate the portions of the clinical trial supported by this award***.
  - **Study Population and Recruitment Process:** Describe the study population, criteria for inclusion/exclusion and the methods that will be used for recruitment/accrual/retention of human subjects.
    - Demonstrate that the research team has access to the proposed study population. If applicable, discuss past efforts in recruiting human subjects from the target population for previous clinical studies. Address any potential barriers to accrual and plans for addressing unanticipated delays.
    - **Enrollment Distribution:** Provide anticipated enrollment table(s) with the proposed enrollment distributed on the basis of sex, race and ethnicity using the Public Health Service (PHS) Inclusion Enrollment Report. The enrollment table(s) should be appropriate to the objectives of the study.
    - Describe how the subject-to-group assignments process will be conducted (e.g., randomization, block randomization, stratified randomization, age-matched controls, alternating group or other procedures), if applicable.
    - Include a detailed description of and justification for the compensation plan if the human subjects will be compensated for participation in the study.
    - For clinical studies proposing to recruit military or VA personnel, refer to the General Application Instructions, Appendix 4, for more information on recruitment process and considerations, payment and confidentiality. If a non-military non-VA population will be used for the proposed clinical study, explain how results obtained will be applicable to military or VA personnel.
  - **Informed Consent Process:** Describe the plan for obtaining informed consent from human subjects. Include relevant draft process documents. **Provide a draft, in English, of the Informed Consent Form.**
  - **Screening Procedures:** List and describe any evaluations that are required to determine eligibility/suitability for study participation and the diagnostic criteria for entry.

- **Risks/Benefits Assessment:** Identify all foreseeable study risks (physical, psychological, social, legal and other). Discuss the importance of the knowledge to be gained in relation to the risks to subjects. Clearly describe measures of risk management and plans for emergency response. Describe known and potential benefits, which may or may not be direct to subjects, in relation to risks.

  Note: Payment and/or other compensation for participation are not considered benefits and must be addressed in Study Population and Recruitment Process.

- **Human Samples:** Describe the types and source(s) of specimens, records or data to be collected and evaluated. Include information about specimen storage (i.e., location, duration, special handling conditions). Describe the identifiers that will be associated with the human specimens and data and provide a list of who has access to subjects' identities. Describe how individually identifiable private information will be protected.

- **Statistical Plan and Data Analysis:** Describe the statistical model and data analysis plan with respect to the study objectives. Specify the approximate number of human subjects to be enrolled. Include a power analysis to demonstrate that the sample size is appropriate to meet the objectives of the study and all proposed correlative studies. If a subpopulation of a recruited sample population will be used for analysis, complete a statistical analysis to ensure appropriate power can be achieved within the subpopulation study.

- **Timeline:** State how many months into the award the anticipated clinical research would be initiated, taking into account any needed regulatory approvals (IRB and DOD Office of Human Research Oversight [OHRO, previously Human Research Protection Office]).

- **Attachment 12: Representations *(Grants.gov submissions only)*: Upload as "RequiredReps.pdf".** All extramural applicants must complete and submit the Required Representations document available on eBRAP.

- **Attachment 13: Suggested Intragovernmental/Intramural Budget Form *(if applicable)*: Upload as "IGBudget.pdf".** If an intramural DOW organization will be a collaborator in the performance of the project, complete a separate budget for that organization using the Suggested Intragovernmental/Intramural Budget form available on eBRAP.

(c) Additional Application Materials:

The following are additional forms for application submission. Follow the instructions specific to the submission portal, as found within the GAI.

Grants.gov	eBRAP.org

i. Research & Related Senior/Key Person Profile (Expanded)

- **Biographical Sketch**
- **Current/Pending Support**

  Intragovernmental applicants must include their internally supported research and development programs.

ii. Research & Related Budget

iii. Project/Performance Site Location(s)

iv. Research & Related Subaward Budget Attachment(s) *(if applicable, Grants.gov submissions only)*

4.4. Other Application Elements

In addition to the complete application package, FY26 PRP EIRA applications also require the following components:

- **Confidential Letters of Recommendation *(minimum of two and maximum of three letters allowed; two pages per letter recommended)***

  The PI should monitor whether the letters have been received in eBRAP by viewing the status in the "Pre-Application Files" tab of the pre-application. The PI will not be able to view the letters.

  The confidential letters should include the following:

  - ***One confidential letter of recommendation from the Mentor, if applicable (and another from the co-Mentor, if applicable)***, describing their commitment to the PI's career development and mentorship in PD research. Mentor letters should address the following:
    - The PI's potential for a highly productive career in PD research.
    - The proposed interactions of the Mentor with the PI during the research project.
    - The mentoring environment, including ongoing PD research in the Mentor's laboratory and in the organization as a whole; resources available; and how this environment will promote the development of the PI as a PD researcher.
    - The degree to which the PI participated in the project development and application preparation; and the degree to which the PI will participate in the execution of the application, if funded.
  - ***Additional confidential letters of recommendation***. Specifically, each letter should offer the writer's perspective on:
    - The PI's qualifications, characteristics, and achievements.
    - The PI's potential for productivity and desire for establishing a successful and independent career in PD research.

- The relevance of the proposed research project to developing the PI's career in PD research.
- The suitability of the Mentor(s), if applicable, and the research environment for providing the PI with a solid foundation to support an independent career in PD research.

If recommended for funding, a quad chart and data management plan compliant with Section 3.c, Enclosure 3, DoD Instructions 3200.12 will be requested.

The government reserves the right to request a revised budget, budget justification and/or additional information for applications recommended for funding.

5. Submission Requirements

5.1. Location of Application Package

Download the application package components for HT942526PRPEIRA from Grants.gov or eBRAP, depending on which submission portal will be used.

5.2. Unique Entity Identifier and System for Award Management

The applicant organization must be registered as an entity in the System for Award Management (SAM), SAM.gov, and receive confirmation of an "Active" status before submitting an application through Grants.gov. Organizations must include the unique entity identifier (UEI) generated by the SAM in applications to this funding opportunity and maintain an active registration in the SAM at all times during which it has an active Federal award or an application under consideration.

5.3. Submission Instructions

The CDMRP uses two portal systems to accept pre- and full application submissions. The workflow below shows which portal system to use for pre- and full application submissions, respectively.

Application Submission Workflow



5.3.1. Pre-Application Submission

All pre-application components must be submitted by the PI through eBRAP.

During the pre-application process, eBRAP assigns each submission a unique log number. This unique log number is required during the full application submission process. The eBRAP log number, application title and all information for the PI, Business Official(s), performing organization, and contracting organization must be consistent throughout the entire

pre-application and full application submission process. Inconsistencies may delay application processing and limit or negate the ability to view, modify and verify the application in eBRAP. Contact the eBRAP Help Desk if any changes need to be made.

When starting the pre-application, PIs should select a Mechanism Option appropriate to their pre-application:

Application Includes:	Select Mechanism Option:
Postdoctoral- or Clinical Fellow-Level PI	Funding Level 1
Early Career-Level PI	Funding Level 2

5.3.2. Full Application Submission

Grants.gov Submissions: Full applications from extramural organizations *must* be submitted through the Grants.gov Workspace.

eBRAP Submissions: Only intramural DOW organizations may submit full applications through eBRAP.

5.3.3. Applicant Verification of Full Application Submission in eBRAP

Independent of the submission portal, once the full application is submitted, it is transmitted to and processed in eBRAP; the transmission to eBRAP may take up to 48 hours. At this stage, the PI and organizational representatives will receive an email from eBRAP instructing them to log in to eBRAP to review, modify and verify the full application submission. ***The Project Narrative and Research & Related Budget Form cannot be changed after the application submission deadline.*** Other application components, including subaward budget(s) and subaward budget justification(s), may be changed until the application verification period ends. The full application cannot be modified once the application verification period ends.

5.4. Submission Dates and Times

The pre-application and full application submission process should be started early to avoid missing deadlines. Regardless of submission portal used, all pre- and full application components must be submitted by the deadlines stipulated in this program announcement. There are no grace periods for deadlines; failure to meet submission deadlines will result in application rejection. ***The DHACA cannot make allowances/exceptions for submission problems encountered by the applicant.***

Submission dates and times are specified in Section 1, Basic Information.

5.5. Intergovernmental Review

Not applicable for this funding opportunity.

6. Application Review Information

6.1. Application Compliance Review

Submitting applications that propose essentially the same research project to different funding opportunities within the same program and fiscal year is prohibited and will result in administrative withdrawal of the duplicative application(s).

While it is allowable to propose similar research projects to different programs within the CDMRP or to other organizations, duplication of funding or accepting funding from more than one source for the same research is prohibited. See the CDMRP's Directive on Research Duplication.

Including classified research data within the application and/or proposing research that may produce classified outcomes or outcomes deemed sensitive to national security concerns may result in application withdrawal.

Members of the FY26 PRP Programmatic Panel must not be involved in any pre-application or full application including, but not limited to, concept design, application development, budget preparation and the development of any supporting documentation, including personal letters of support/recommendation for the research and/or PI. Programmatic panel members ***may*** provide letters to confirm PI eligibility and access to laboratory space, equipment and other resources necessary for the project if that is part of their regular roles and responsibilities (e.g., as Department Chair). ***A list of the FY26 PRP Programmatic Panel members can be found on the CDMRP website.***

Additional restrictions and associated administrative responses are outlined in Section 9.2, Administrative Actions.

6.2. Review Criteria

6.2.1. Pre-Application Screening Criteria

Pre-applications submitted to this funding opportunity are used for program planning purposes only (e.g., reviewer recruitment) and will not be screened.

6.2.2. Peer Review Criteria

To determine technical merit, all applications will be evaluated individually according to the following **scored criteria**, which are of equal importance:

- **Personnel**
  - **Principal Investigator**
    - How well the PI's achievements (as reflected by academic performance, awards, honors, and/or previous publications and funding) indicate the potential for a successful career as a PD researcher.
    - To what extent the PI's stated career goals demonstrate a strong personal commitment to pursuing an independent career as a leader in PD research.
    - To what extent the letters of recommendation from the Mentor(s), if applicable, and others support the PI's potential for a highly productive career as a PD researcher.

  - Whether the PI's proposed level of effort, if not 100%, is appropriate for successful completion of the proposed work.

- **Mentor(s)** ***(required for Funding Level 1)***
  - Whether there is at least one Mentor who is an established PD researcher, as evidenced by a demonstrated record of active funding and recent publications in PD research.
  - How the Mentor (and co-Mentor, if applicable) will assist the PI throughout the period of performance in developing toward independence in PD research.
  - To what extent the Mentor's track record for training young investigators indicates the potential for successful mentoring of the PI in PD research.
  - Whether the Mentor letter(s) indicates a high level of commitment to the PI's development as a PD researcher.
  - Whether the quality of the application suggests that the Mentor(s) provided appropriate guidance in its preparation.

- **Research Strategy and Feasibility**
  - How well the preliminary and/or published data, relevant literature, and scientific rationale support the proposed research project.
  - To what extent the proposed research project is feasible as described, and according to the statistical analysis plan.
  - Whether the strategy for considering sex as a biological variable is appropriate to the objectives of the study or whether the justification for a single-sex study is sufficiently strong.
  - If animal studies are included, how well studies are designed to achieve reproducible and rigorous results, including the choice of model and the endpoints/outcomes to be measured.
  - If human subjects or human biological samples will be used, how well the plan for the recruitment of subjects, including women and minorities, or the acquisition of samples is justified and appropriate to accomplish the proposed work.
  - If applicable, whether data will be appropriately reported and documented to support a regulatory filing with the FDA.
  - How well the application identifies potential problems and addresses alternative approaches.
  - How well the SOW indicates a feasible plan and timeline to conduct the research and provides clearly defined research milestones to be accomplished by the end of each year in the period of performance.

- **Impact**
  - To what degree the proposed short- and long-term outcomes of the proposed research will support the PRP's mission of supporting high-impact research that intends to decrease risk, slow progression or ease symptoms of Parkinson's disease.
  - How well the proposed research addresses one or more of the FY26 PRP Focus Areas.
  - To what extent the proposed research is relevant to the health care needs of Service Members, Veterans, their Families, and/or Family readiness of Service Members.

- **Research Outcomes Plan**
  - To what extent the Research Outcomes Plan outlines the project's anticipated research outcome(s), including knowledge product(s), clinical products for development, etc.
  - To what extent the plan describes the methods and strategies proposed to move the anticipated research outcomes to the next phase of development or clinical application after successful completion of the project.
  - To what extent the plan describes the funding strategy to transition to the next level of investigation, development, and/or commercialization (e.g., partners, internal/external funding opportunities to be applied for).
  - To what extent the application discusses a plan for management of intellectual property necessary for the development and/or commercialization of products or technologies supported under this award.
- **Researcher Development Plan *(required for Funding Level 1)***
  - How well the application has outlined an individualized plan that will provide the PI with an opportunity to develop a research project, investigate a problem or question in PD research.
  - How well the application has outlined an individualized plan that will enable the PI to acquire the necessary skills, competence, and expertise to successfully complete the proposed research project.
  - How well the application has outlined an individualized plan that will effectively prepare the PI for a successful career as an independent PD researcher.
  - To what extent the Mentor(s) will support the Researcher Development Plan.
  - To what extent the scientific environment at the primary institution and collaborating institution(s) are appropriate for the proposed research and career development activities, including professional interaction with established PD researchers.

In addition, the following criteria will also contribute to the overall evaluation of the application but will not be individually scored and are therefore termed **unscored criteria**.

Unscored criteria are not assigned numerical scores but are evaluated qualitatively and may be discussed during panel review. Significant strengths or weaknesses in unscored criteria may influence the overall score and funding recommendation. For example, an inadequate budget or poorly written application may reduce confidence in the application despite strong scored criteria.

- **Budget**
  - Whether the budget is appropriate for the proposed research.
- **Environment**
  - To what extent the scientific environment and level of institutional support is appropriate for the proposed research project.
  - How well the research requirements are supported by the availability of and accessibility to facilities and resources.
- **Data and/or Research Sharing Plan**
  - To what extent the plan for sharing of project data and research resources is appropriate and reasonable and includes dissemination to affected communities, study participants

and/or the scientific community. If applicable, whether specific repository(ies) are named where data and research resources arising from the project will be stored.

- **Application Presentation**
  - To what extent the writing, clarity and presentation of the application components influence the review.

6.2.3. Programmatic Review

To make funding recommendations and select the application(s) that, individually or collectively, will best achieve the program objectives, the following criteria are used by programmatic reviewers:

- Ratings and evaluations of peer reviewers
- Relevance to the priorities of the FY26 PRP, as evidenced by the following:
  - Adherence to the intent of the funding opportunity
  - Program portfolio balance
  - Impact and relevance to military health
  - Programmatic relevance to the FY26 PRP Focus Areas

6.3. Application Review and Selection Process

6.3.1. Pre-Application

There is no review and selection process for pre-applications submitted to this funding opportunity. ***The CDMRP will NOT provide an invitation to submit a full application after pre-application submission***. Applicants are encouraged to develop pre-application and full application components concurrently and submit a full application AFTER successful submission of the pre-application.

6.3.2. Full Application

All applications are evaluated by scientists, clinicians and consumers in a two-tier review process. The first tier is **peer review**, the evaluation of applications against established criteria to determine technical merit, where each application is assessed for its own merit, independent of other applications. The second tier is **programmatic review**, a comparison-based process in which applications with high scientific and technical merit are further evaluated for programmatic relevance. Final recommendations for funding are subject to review and approval by a designated official. ***The highest-scoring applications from the first tier of review are not automatically recommended for funding. Funding recommendations depend on various factors as described in Section 6.2.3, Programmatic Review.*** Additional information about the two-tier process used by the CDMRP can be found on the CDMRP website.

Funding of applications received is contingent upon the availability of federal funds for this program, the number of applications received, the quality and merit of the applications as evaluated by peer and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds.

6.4. Risk, Integrity and Performance Information

Prior to making an assistance agreement award where the federal share is expected to exceed the simplified acquisition threshold, as defined in the Code of Federal Regulations, Title 2, Part 200.1 (2 CFR 200.1), over the period of performance, the federal awarding agency is required to review and consider any information about the applicant that is available in the SAM.

An applicant organization may review the SAM and submit comments on any information currently available about the organization that a federal awarding agency previously entered. The federal awarding agency will consider any comments by the applicant, in addition to other information in the designated integrity and performance system, in making a judgment about the applicant's integrity, business ethics and record of performance under federal awards when determining a recipient's qualification prior to award, according to the qualification standards of the Department of Defense Grant and Agreement Regulations (DoDGARs), Section 22.415.

In accordance with National Security Presidential Memorandum-33 and all associated laws, all fundamental research funded by the DOW must be evaluated for affiliations with foreign entities. All applicant organizations must disclose foreign affiliations of all key personnel named on applications. Failure to disclose foreign affiliations of key personnel shall lead to withdrawal of recommendations to fund applications. Applicant organizations may be presented with an opportunity to mitigate identified risks, particularly those pertaining to influence from foreign entities specified in law. Implementation of mitigation discussions and utilization of the DOD Component Decision Matrix must decrease risk of foreign influence in accordance with the above-mentioned laws and guidance prior to award.

7. Federal Award Notices

For each compliant full application received, the organizational representative(s) and PI will receive email notification when the funding recommendations are posted to eBRAP, typically within 6 weeks after programmatic review. At this time, each PI will receive a peer review summary statement on the strengths and weaknesses of the application and an information paper describing the application receipt and review process for the PRP award mechanisms. The information papers and a list of organizations and PIs recommended for funding are also posted on the program's page within the CDMRP website. After all awards are made, the CDMRP includes individual award information in a searchable database.

If an application is recommended for funding, after the email notification is posted to eBRAP, a government representative will contact the person authorized to negotiate on behalf of the recipient organization.

Only an appointed DHACA Grants Officer may obligate the government to the expenditure of funds to an extramural organization. No commitment on the part of the government should be inferred from discussions with any other individual. ***The award document signed by the Grants Officer is the official authorizing document (i.e., assistance agreement).***

Intragovernmental obligations of funding will be made according to the terms of a negotiated Inter-Agency Agreement and managed by a CDMRP Science Officer.

Funding obligated to ***intragovernmental and intramural DOW organizations*** will be sent through the Military Interdepartmental Purchase Request (MIPR), Funding Authorization Document (FAD) or Direct Charge Work Breakdown Structure processes. Transfer of funds is contingent upon appropriate safety and administrative approvals. Intragovernmental and intramural DOW investigators and collaborators must coordinate receipt and commitment of funds through their respective Resource Manager/Task Area Manager/Comptroller or equivalent Business Official.

An organization may, at its own risk and without the government's prior approval, incur obligations and expenditures to cover costs up to 90 days before the beginning date of the initial budget period of a new award.

8. Post-Award Requirements

8.1. Administrative and National Policy Requirements

Applicable requirements in the DoDGARs found in 32 CFR, Chapter I, Subchapter C, and 2 CFR, Chapter XI, apply to grants and cooperative agreements resulting from this program announcement.

The GAI contain information regarding administrative requirements and national policy requirements.

Refer to full text of the latest DoD R&D Terms and Conditions and the DHACA Terms and Conditions for further information.

If there are delinquencies in technical reporting requirements for any existing DHA or U.S. Army Medical Research and Development Command awards at the applicant organization, DHACA will not issue any new awards to the applicant organization until all delinquent reports have been submitted.

Applications recommended for funding that involve animals, human data, human specimens, human subjects or human cadavers must be reviewed for compliance with federal animal and/or human subjects protection requirements and must be approved by the DHA R&D Office of Research and Regulatory Compliance (ORRC), prior to implementation. This administrative review requirement is in addition to the local IACUC, IRB or Ethics Committee (EC) review.

8.2. Reporting

Annual technical progress reports and quad charts, as well as a final technical progress report and quad chart, will be required. Annual and final technical progress reports must be prepared in accordance with the Research Performance Progress Report (RPPR).

The Award Terms and Conditions will specify whether additional and/or more frequent reporting is required.

PHS Inclusion Enrollment Reporting *(only required for clinical research studies)*: Enrollment reporting on the basis of sex, race, and/or ethnicity using the PHS Inclusion Enrollment Report will be required with each annual and final progress report. The PHS Inclusion Enrollment Report is available on eBRAP.

Awards resulting from this program announcement may entail additional reporting requirements related to recipient integrity and performance matters. Recipient organizations that have federal contract, grant and cooperative agreement awards with a cumulative total value greater than $10M are required to provide information to the SAM about certain civil, criminal and administrative proceedings that reached final disposition within the most recent 5-year period and that were connected with their performance of a federal award. These recipients are required to disclose, semiannually, information about criminal, civil and administrative proceedings as specified in the applicable Representations.

8.3. Additional Requirements

Unless otherwise restricted, changes in the organization will be allowed on a case-by-case basis, provided the intent of the award mechanism is met.

An organizational transfer of an award will not be allowed in the last year of the original period of performance or any extension thereof.

9. Other Information

9.1. Program Announcement Version

Questions related to this program announcement should refer to the program name, the program announcement name and the program announcement version code CD26_01d.

9.2. Administrative Actions

After receipt of full applications, the following administrative actions may occur.

9.2.1. Rejection

The following will result in administrative rejection of the full application:

- The Project Narrative is missing.
- The Budget is missing.
- The Pre-application was not submitted.
- Attachment 7: Letter of Eligibility is missing.
- Attachment 9: Researcher Development Plan is missing from the Funding Level 1 application.

9.2.2. Modification

- Pages exceeding the specified limits will be removed prior to reviewing all documents.
- Documents not requested will be removed.

9.2.3. Withdrawal

The following may result in administrative withdrawal of the full application:

- A member of the FY26 PRP Programmatic Panel is named as being involved in the development or execution of the research proposed or is found to have assisted in the pre-application or application processes.
- The application includes the name(s) of personnel from either of the CDMRP peer or programmatic review companies for which conflicts cannot be adequately mitigated. For FY26, the identities of the peer review contractor and the programmatic review contractor may be found on the CDMRP website.
- Personnel from applicant or collaborating organizations are found to have contacted persons involved in the review or approval process to gain protected evaluation information or to influence the evaluation process.
- The application from an extramural organization, including non-DOW federal agencies, is received through eBRAP.
- The federal government recipient organization (including an intramural DOW organization): (a) cannot accept and execute the entirety of the requested budget in FY26 funds; and/or (b)

cannot coordinate the use of contractual, assistance or other appropriate agreements to provide funds to collaborators.

- The application fails to conform to this program announcement description.
- The application includes URLs, with the exception of links in the References Cited and Publication and/or Patent sections.
- The application includes research data that are classified and/or proposes research that may produce classified outcomes, or outcomes deemed sensitive to national security concerns.
- The same research project is submitted to different funding opportunities within the same program and fiscal year.
- The PI does not meet the eligibility criteria.
- Two confidential letters of recommendation are not submitted.
- The application does not address at least one of the FY26 PRP Focus Areas.
- Attachment 10: Animal Research Plan is missing, for applications proposing animal studies.
- A clinical trial is proposed.

9.2.4. Withhold

Applications that appear to involve research misconduct will be administratively withheld from further consideration pending organizational investigation. The organization will be required to provide the findings of the investigation to the DHACA Grants Officer for a determination of the final disposition of the application.

Appendix 1. Full Application Submission Checklist

Full Application Components	Uploaded
SF424 Research & Related Application for Federal Assistance ***(Grants.gov submissions only)***	☐
Summary (Tab 1) and Application Contacts (Tab 2) ***(eBRAP submissions only)***	☐
Attachments	
Project Narrative – Attachment 1, upload as "ProjectNarrative.pdf"	☐
Supporting Documentation – Attachment 2, upload as "Support.pdf"	☐
Technical Abstract – Attachment 3, upload as "TechAbs.pdf"	☐
Lay Abstract – Attachment 4, upload as "LayAbs.pdf"	☐
Statement of Work – Attachment 5, upload as "SOW.pdf"	☐
Impact Statement – Attachment 6, upload as "Impact.pdf"	
Letter of Eligibility – Attachment 7, upload as "Eligibility.pdf"	
Research Outcomes Plan – Attachment 8, upload as "Outcomes.pdf"	☐
Researcher Development Plan – Attachment 9, upload as "ResearcherDev.pdf"	
Animal Research Plan – Attachment 10, upload as "AnimalResPlan.pdf"	
Human Subjects/Samples Acquisition and Safety Procedures – Attachment 11, upload as "HumProc.pdf"	
Representations ***(Grants.gov submissions only)*** **– Attachment 12, upload as "RequiredReps.pdf"**	☐
Suggested Intragovernmental/Intramural Budget Form ***(if applicable)*** **– Attachment 13, upload as "IGBudget.pdf"**	☐
Additional Application Materials	
Research & Related Senior/Key Person Profile (Expanded)	☐
Attach Biographical Sketch for Senior/Key Persons (Biosketch_LastName.pdf)	☐
Attach Current/Pending Support for Senior/Key Persons (Support_LastName.pdf)	☐
Research & Related Budget	☐
Project/Performance Site Location(s)	☐
Research & Related Subaward Budget Attachment(s) ***(if applicable)***	☐
Additional Application Components	
Confidential Letters of Recommendation	☐

Appendix 2. Acronym List

ARRIVE	Animal Research: Reporting of In Vivo Experiments
CDMRP	Congressionally Directed Medical Research Programs
CFR	Code of Federal Regulations
CONSORT	Consolidated Standards of Reporting Trials
DHA	Defense Health Agency
DHA R&D	Defense Health Agency Research and Development
DHACA	Defense Health Agency Contracting Activity
DOD	U.S. Department of Defense
DoDGARs	Department of Defense Grant and Agreement Regulations
DOW	U.S. Department of War
eBRAP	Electronic Biomedical Research Application Portal
EC	Ethics Committee
EIRA	Early Investigator Research Award
ET	Eastern Time
FAD	Funding Authorization Document
FY	Fiscal Year
GAI	General Application Instructions
IACUC	Institutional Animal Care and Use Committee
IRB	Institutional Review Board
LOI	Letter of Intent
M	Million
MIPR	Military Interdepartmental Purchase Request
NIH	National Institutes of Health
OHRO	Office of Human Research Oversight (previously Human Research Protection Office)
ORRC	Office of Research and Regulatory Compliance
PD	Parkinson’s Disease
PDF	Portable Document Format
PHS	Public Health Service
PI	Principal Investigator
PRP	Parkinson’s Research Program
R&D	Research and Development
RPPR	Research Performance Progress Report
SAM	System for Award Management
SF424 R&R	Standard Form 424 (Application for Federal Assistance, Research & Related)

SOW	Statement of Work
SPIRIT	Standard Protocol Items: Recommendations for Interventional Trials
STROBE	STrengthening the Reporting of OBservational Studies in Epidemiology
UEI	Unique Entity Identifier
URL	Uniform Resource Locator
USC	United States Code
VA	U.S. Department of Veterans Affairs